ClinicalTrials.Veeva

Menu

Trial of Long-term Therapeutic Hypothermia for Poor-grade Aneurysmal Subarachnoid Hemorrhage

Capital Medical University logo

Capital Medical University

Status

Unknown

Conditions

Aneurysmal Subarachnoid Hemorrhage
Hypothermia

Treatments

Procedure: Zoll 2000 and/or CureWrap 3500 cooling system

Study type

Interventional

Funder types

Other

Identifiers

NCT03442608
LTHSAH-1

Details and patient eligibility

About

This study is a prospective, multi-centre, randomized,controlled trial to compare the efficacy of long-term mild hypothermia with normothermic intensive management in patients with poor-grade aneurysmal subarachnoid hemorrhage.

The primary hypothesis is that the induction of mild hypothermia (maintained at 32-35℃) for at least 5 days would improve the outcome of patients at six months post hemorrhage compared with normothermia.

Full description

Aneurysmal subarachnoid hemorrhage (aSAH), especially poor-grade aSAH, is a medical emergency with very high morbidity and mortality rates. SAH constitutes a major public health concern in developed and developing countries. There were several clinical trials of hypothermia for aSAH conducted, however, with conflicting results.

Hypothermia therapy treatment is currently used in our department and other large neurosurgical centers across China to decrease the intracranial pressure (ICP), mitigate some of the destructive processes, and improve the functional outcome of patients with poor-grade aSAH. When the decision was made, the patients would be placed in wrapped cooling blankets or intravascular cooling device after they were sedated, intubated and mechanically ventilated. The patients would receive continuous infusions of some drugs using an infusion pump to prevent shivering. Once the patient's rectal, nasopharyngeal or blood temperature reached 32˚C, it was kept at approximately that temperature (32-35˚C) 3 to 7 days. Then the patients were passively rewarmed to a temperature of 36 to 37˚C at a rate no greater than 0.25˚C/hour, by gradual adjustment of the blanket thermostat.

The present multi-center, randomized controlled trials is designed to investigate the efficacy and safety of long-term (3 days) mild hypothermia versus normothermia on the outcome of patients with poor-grade aSAH. The primary outcome is the neurological function assessed at 1,3, 6 months post injury with the Glasgow Outcome Score (GOS). Additionally, the following data will also be recorded and compared: the baseline data, Glasgow Coma Score,imaging examination (e.g. CT scan), intracranial pressure, laboratory tests (e.g. blood routine test, liver and kidney function, blood gas analysis, etc), the complications (e.g. pneumonia, significant bleeding) and so on.

Enrollment

200 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 18 - 65 years within 72 hours after subarachnoid hemorrhage;
  • Neurosurgical clipping or coiling for aneurysm;
  • Hunt-Hess IV-V scale;
  • The intracranial pressure is more than 20 mmHg.

Exclusion criteria

  • GCS of 3 with bilateral fixed and dilated pupils;
  • No spontaneous breathing or cardiac arrest at the scene of hemorrhage;
  • No consent;
  • Pregnancy.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

200 participants in 2 patient groups, including a placebo group

mild hypothermia
Experimental group
Description:
Device: Zoll 2000 and/or CureWrap 3500 cooling system,lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
Treatment:
Procedure: Zoll 2000 and/or CureWrap 3500 cooling system
northermia
Placebo Comparator group
Description:
normal physical cooling methods,like ice bag, conditionally required.
Treatment:
Procedure: Zoll 2000 and/or CureWrap 3500 cooling system

Trial contacts and locations

0

Loading...

Central trial contact

Xin Qu, MD,PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems